Rozenn Le Berre

Title: Innovations in Respiratory Infection Treatment by Rozenn Le Berre

Introduction

Rozenn Le Berre is an accomplished inventor based in Brest, France. She has made significant contributions to the field of respiratory infections, particularly in the treatment of conditions affecting patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD). With two patents to her name, her work focuses on innovative methods to combat chronic respiratory infections.

Latest Patents

Rozenn Le Berre's latest patents involve methods of treating pseudomonas aeruginosa (PA) respiratory infections. These infections are known to lead to chronic respiratory issues, especially in patients suffering from cystic fibrosis and COPD, which are characterized by high morbidity rates. Her research includes screening Lactobacilli derived from cystic fibrosis expectorations for their ability to inhibit two virulence factors of PA: elastase and pyocyanin. The effectiveness of intranasal administration of Lactobacilli on PA murine pneumonia was evaluated, with the primary outcome being the bacterial lung load measured 24 hours after PA-induced pneumonia. The study also assessed the role of chemokines and measured pro and anti-inflammatory bronchoalveolar lavage (BAL) rates. The results indicated that administering a Lactobacilli cocktail 18 hours prior to PA lung infection significantly reduced the lung bacterial load at 24 hours post-infection. Although the underlying mechanisms require further exploration, an immunomodulatory effect may be involved, particularly through the recruitment of neutrophils.

Career Highlights

Rozenn Le Berre has worked with notable institutions such as the Institut National de la Santé et de la Recherche Médicale and the Centre Hospitalier Régional et Universitaire de Brest. Her career reflects a strong commitment to advancing medical research and developing effective treatments for respiratory infections.

Collaborations

She has collaborated with colleagues including Marie-Sarah Fangous and Gwenaelle Le Blay, contributing to her innovative research efforts.

Conclusion

Rozenn Le Berre's work exemplifies the importance of innovation in treating respiratory infections, particularly for vulnerable patient populations. Her contributions are paving the way for new therapeutic approaches in the medical field.